Merck & Co. may be on to something with their latest Type 2 diabetes drug. Unlike their daily DPP-4 inhibitor Januvia, this Phase II drug has shown to lower blood glucose in a once weekly oral medicine.
The drug, known as MK-3102, had a greater effect the higher the hose. In a 12 week trial the doses tested were between .25 mg to 25 mg. The drug had a significant blood glucose lowering result compared to a placebo. The researchers commented that the overall performance of the once-weekly MK-3102 had similar outcomes to the Phase II trial of once-daily Januvia.
Is all that glitters gold? We’ll have to see. As with the unforeseen events following the release of GlaxoSmithKline’s Avandia, Merck will be expected to demonstrate the heart safety of MK-3102 in its Phase III trials.
Spoiler alert. Merck is being forthcoming about the once weekly drug. Although it seems to help stabilize glucose levels for people with Type 2 diabetes, it is expected to work either alone or as an adjunct treatment with other anti-diabetes medicine or insulin.
At the end of the day, Merck is banking on the ability to lessen the load of daily pills. If that’s the goal, it may be a winner. Now where’s that SmartInsulin, Merck!?? I hate to perseverate on the issue but some things get bought out to get fitted for cement shoes. Glucose-sensing insulin would help people with Type 1 diabetes as much as it would help those with Type 2 diabetes. Just sayin’.
Visit Your Diabetes Health for more resources about health.